RE:RE:That's it for me.Thanks for your note and interest in
"The pre-BTD submission is a consultation with the FDA for feedback and guidance regarding an actual BTD submission.
I don’t believe pre-BTD is material as you stated below, regardless, once we have received and reviewed the feedback and guidance from the FDA, we will likely provide an update to the market."
Nothing terrible here I just did not like the "once we have received" and "reviewed the feedback" ---
[obviously Matthew has to be careful with his language. ]
This is me not being able to lose what I have gained + learning about the CEO's ban for overstating things + knowing the market is kiddish.
This does NOT mean Theralase is not going to thrive.
Just a sensitive gut on my part.